Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

This open-label phase 2 study (CONTRALTO) assessed the safety and efficacy of BCL-2 inhibitor venetoclax (VEN) plus rituximab (R), and VEN plus bendamustine (B) and R, vs B + R (BR) alone in relapsed/refractory (R/R) follicular lymphoma. Patients in the chemotherapy-free arm (arm A: VEN + R) receive...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Zinzani, Pier Luigi, Flinn, Ian W., Yuen, Sam L. S., Topp, Max S., Rusconi, Chiara, Fleury, Isabelle, Le Dû, Katell, Arthur, Christopher, Pro, Barbara, Gritti, Giuseppe, Crump, Michael, Petrich, Adam, Samineni, Divya, Sinha, Arijit, Punnoose, Elizabeth A., Szafer-Glusman, Edith, Spielewoy, Nathalie, Mobasher, Mehrdad, Humphrey, Kathryn, Kornacker, Martin, Hiddemann, Wolfgang
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735159/
https://ncbi.nlm.nih.gov/pubmed/32785666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005588
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi